Hundreds of REI shoppers know that staying dry in rainy weather is easy when you have a good rain jacket, which is why they ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the most promising stocks under $100. On October 9, BofA raised the firm’s price target on Teva to $24 from $22, while keeping a Buy rating ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best drug stocks to buy right now. Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced on September 9 that it attained Fast ...

If you’re wondering what’s next for Teva Pharmaceutical Industries (NYSE:TEVA), the company’s latest move might catch your attention. Teva just announced the FDA approval and U.S. launch of its ...

Teva's generic Saxenda is the first generic GLP-1 indicated for weight loss. Richardsen added, “This is the fifth first-to-market entry of a Teva generic this year and is an important addition to Teva ...

Israeli multinational pharmaceutical company Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) hosted 2025 Innovation & Strategy Day on Thursday to launch the acceleration phase of its “Pivot to Growth” ...

BD9 blocks both TSLP and IL-13, two major drivers of TH2 inflammation. Biolojic to receive milestone payments tied to BD9 development progress. Special Access: Get Market Moving News Up to 15 Minutes ...

"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." Once summer hits, walking sandals can be more comfortable than sneakers (although we do appreciate a good ...

Teva's Q4 earnings reveal significant headwinds, including declining U.S. generics revenue and rising costs in the API business, impacting overall profitability. Branded drugs like Austedo and Uzedy ...

GOLETA, Calif.--(BUSINESS WIRE)--Teva®, a division of Deckers Brands (NYSE: DECK), announces the arrival of its spring-summer 2025 collection and new anthem “For Playground Earth,” which was created ...

Teva Pharmaceutical Industries' Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. Management's cautious 2025 guidance sets a low bar, likely to be ...